Description
Phenytoin
Generic Medicine InfoPatient Medicine Information
This information is not country-specific. Please refer to the local prescribing information.
Generic Medicine Info
Indications and Dosage Intramuscular Adult: 100-200 mg 4 hourly during surgery and continued post-operatively for 48-72 hours, reduced to a maintenance dose of 300 mg daily thereafter, adjusted according to plasma concentrations. Use an alternative route (e.g. intubation) if >1 week of IM therapy is required.
Intravenous Adult: As an adjunct with a benzodiazepine (e.g. diazepam, lorazepam): Initially, 10-15 mg/kg via slow inj or intermittent infusion at a rate of not more than 50 mg/min. Maintenance: 100 mg (PO or IV) given 6-8 hourly.
Oral Adult: Initially, 3-4 mg/kg daily or 150-300 mg daily given as a single dose or in divided doses, adjust subsequent doses if necessary. Maintenance: 200-500 mg daily. |
Special Patient Group Pharmacogenomics: Individuals who are carriers of human leukocyte antigen (HLA)-B*15:02 may be at risk of phenytoin induced cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). HLA-B*15:02 allele is found almost exclusively across broad areas of Asia. Patients with ancestry from North China, Taiwan, Hong Kong, Thailand, Malaysia, India and parts of the Philippines have a higher likelihood of being a carrier of this allele. Consider HLA-B*15:02 genotype test as a screening tool in these patients. Results are interpreted as “positive” if one or two copies of HLA-B*15:02 are present or as “negative” if no copies of HLA-B*15:02 are present. Avoid use of phenytoin in patients who are HLA-B*15:02-positive. Not all phenytoin-induced SJS/TEN can be attributed to HLA-B*15:02. All patients taking phenytoin should be appropriately monitored for severe cutaneous adverse reactions as these reactions can still occur infrequently in HLA-B*15:02-negative patients of any ethnicity. |
Administration Should be taken with food. When administering to patients on nasogastric or other enteral feeds, do not administer feeds 2 hr before or after a dose. Be consistent throughout therapy in relation to feed times. Do not switch dosage forms/brands w/o prior consideration. |
Reconstitution IV Infusion: Dilute in 50-100 mL NaCl 0.9% to a provide a final concentration not exceeding 10 mg/mL. |
Incompatibility Dextrose-containing solutions. |
Contraindications History of acute hepatotoxicity attributable to phenytoin. Concomitant use with delavirdine. Inj: Sinus bradycardia, sino-atrial block, 2nd and 3rd degree AV block, Adams-Stokes syndrome. |
Special Precautions Patient with history of adverse haematologic reaction to any drug; diabetes mellitus, hypotension, cardiac disease; conditions associated with low serum albumin levels; hypothyroidism, porphyria. Critically ill, and debilitated patients. Patients who are positive for HLA-B*15:02 allele. Not indicated for the treatment of absence (petit mal) seizures, seizures due to hypoglycaemia or other metabolic causes. Avoid abrupt withdrawal. Hepatic and renal impairment. Pregnancy and lactation. |
Adverse Reactions Significant: Bone effects (e.g. osteopenia, osteoporosis, osteomalacia, bone fractures), vitamin D deficiency, hypocalcaemia, hypophosphataemia, acute hepatotoxicity, acute hepatic failure, hypersensitivity, suicidal ideation and behaviour. IV: extravasation; hypotension, severe cardiac arrhythmia (rapid administration). |
IM/IV/Parenteral/PO: D |
Patient Counseling Information This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery. |
Monitoring Parameters Monitor CBC, LFT, vitamin D status, plasma phenytoin concentrations? signs of suicidal ideation. |
Overdosage Symptoms: Nystagmus, ataxia, dysarthria, apnoea, tremor, lethargy, nausea, vomiting, coma, hypotension, respiratory and circulatory depression. Management: Symptomatic and supportive treatment. Stomach emptying may be done within 4 hours of ingestion. Employ supportive measures (e.g. oxygen, vasopressors, assisted ventilation) for CNS, respiratory and CV depression. May consider haemodialysis. |
Drug Interactions Increased serum levels with salicylates; antibacterial agents (e.g. chloramphenicol, clarithromycin, isoniazid, sulfadiazine, sulfamethoxazole-trimethoprim, sulfonamides); anticonvulsants (e.g. oxcarbazepine, succinimides, topiramate); antifungal agents (e.g. amphotericin B, fluconazole, itraconazole, ketoconazole, miconazole); antineoplastic agents (e.g. capecitabine, fluorouracil); benzodiazepines/psychotropic drugs (e.g. disulfiram, methylphenidate, trazodone); CV agents (e.g. amiodarone, diltiazem, nifedipine); cimetidine, fluvastatin, tacrolimus, tolbutamide, omeprazole; serotonin re-uptake inhibitors (e.g. fluoxetine, fluvoxamine). Decreased serum levels with vigabatrin; antineoplastic agents (e.g. bleomycin, carboplatin, cisplatin, doxorubicin); sucralfate, reserpine, folic acid, rifampicin; antiretroviral (e.g. fosamprenavir, nelfinavir, ritonavir); theophylline, diazoxide. May increase or decrease serum levels with ciprofloxacin; psychotropic agents (e.g. chlordiazepoxide, diazepam, phenothiazines). May alter serum levels and/or effects of doxycycline; anticonvulsants (e.g. carbamazepine, lamotrigine, phenobarbital, Na valproate, valproic acid); antifungal agents (e.g. posaconazole, voriconazole); methotrexate; antiretrovirals (e.g. efavirenz, fosamprenavir, indinavir, lopinavir/ritonavir, ritonavir, saquinavir); theophylline; CV agents (e.g. digoxin, disopyramide, mexiletine, nicardipine, nimodipine, verapamil), warfarin, furosemide; HMG-CoA reductase inhibitors (e.g. atorvastatin, fluvastatin, simvastatin); oestrogens, oral contraceptives; neuromuscular blocking agents (e.g. pancuronium, rocuronium, vecuronium); methadone, tolbutamide; psychotropic agents/antidepressants (e.g. clozapine, paroxetine, quetiapine, sertraline); vitamin D. |
Food Interaction Decreased plasma concentrations with St John’s wort. Acute alcohol intake may increase phenytoin serum levels, while chronic use may decrease serum levels. |
Lab Interference Falsely high plasma phenytoin concentrations when measured by immunoanalytical techniques. Falsely low results for dexamethasone and metyrapone tests. Increased serum levels of thyroid stimulating hormone (TSH, usually in the absence of clinical hypothyroidism). |
Action Description: Phenytoin, a hydantoin antiepileptic, stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of Na ions across cell membranes in the motor cortex during generation of nerve impulses. |
Chemical Structure
Phenytoin Source: National Center for Biotechnology Information. PubChem Database. Phenytoin, CID=1775, https://pubchem.ncbi.nlm.nih.gov/compound/Phenytoin (accessed on Jan. 22, 2020) |
Storage Tab/cap/susp: Store between 20-25°C. Protect from light and moisture. Soln for inj: Store between 15-30°C. |
MIMS Class |
ATC Classification N03AB02 – phenytoin ; Belongs to the class of hydantoin derivatives antiepileptics. |